Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Amble vs Boston Medical Group

Amble
Graded #212

Higher grade

vs+3.8999999999999986
Boston Medical Group
Graded #279

Lower grade

The verdict

Amble takes it — 65.8/100 to 61.9/100.

Amble grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth weight loss provider offering compounded semaglutide and tiered tirzepatide programs.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAmble +7
61
54
Dose & formulationAmble +12
64
52
Clinical oversightBoston Medical Group +10
79
89
Labs & monitoringBoston Medical Group +1
52
53
FulfillmentAmble +16
81
65
Contract termsEven
55
55
Amble · left barBoston Medical Group · right bar

The numbers

MetricAmbleBoston Medical Group
WeighScore65.8/10061.9/100
GradeCC
Scorecard rank#212#279
Semaglutide$179/mo (starting dose, compounded)$199/mo (starting strength, rising with dose, compounded)
Tirzepatide$289/mo (starting dose, compounded)Not disclosed
CoverageAll 50 states7 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Amble

Graded #212 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard